Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar;42(2):e3250.
doi: 10.1002/hon.3250.

How receptor tyrosine kinase-like orphan receptor 1 meets its partners in chronic lymphocytic leukemia

Nayla Mouawad  1 , Edoardo Ruggeri  1 , Guido Capasso  1 , Leonardo Martinello  1 , Andrea Visentin  1 , Federica Frezzato  1 , Livio Trentin  1
Affiliations
Review

How receptor tyrosine kinase-like orphan receptor 1 meets its partners in chronic lymphocytic leukemia

Nayla Mouawad et al. Hematol Oncol. 2024 Mar.

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in western societies, recognized by clinical and molecular heterogeneity. Despite the success of targeted therapies, acquired resistance remains a challenge for relapsed and refractory CLL, as a consequence of mutations in the target or the upregulation of other survival pathways leading to the progression of the disease. Research on proteins that can trigger such pathways may define novel therapies for a successful outcome in CLL such as the receptor tyrosine kinase-like orphan receptor 1 (ROR1). ROR1 is a signaling receptor for Wnt5a, with an important role during embryogenesis. The aberrant expression on CLL cells and several types of tumors, is involved in cell proliferation, survival, migration as well as drug resistance. Antibody-based immunotherapies and small-molecule compounds emerged to target ROR1 in preclinical and clinical studies. Efforts have been made to identify new prognostic markers having predictive value to refine and increase the detection and management of CLL. ROR1 can be considered as an attractive target for CLL diagnosis, prognosis, and treatment. It can be clinically effective alone and/or in combination with current approved agents. In this review, we summarize the scientific achievements in targeting ROR1 for CLL diagnosis, prognosis, and treatment.

Keywords: CLL; ROR1; diagnosis; prognosis; receptor tyrosine kinase; therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. Masiakowskis P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase‐like domain. J Biol Chem. 1992;267(36):26181‐26190. https://doi.org/10.1016/s0021‐9258(18)35733‐8
    1. Witze ES, Litman ES, Argast GM, Moon RT, Ahn NG. Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors. Science. 2008;320(5874):365‐369. (1979). https://doi.org/10.1126/science.1151250
    1. Kamizaki K, Endo M, Minami Y, Kobayashi Y. Role of noncanonical Wnt ligands and Ror‐family receptor tyrosine kinases in the development, regeneration, and diseases of the musculoskeletal system. Dev Dynam. 2021;250(1):27‐38. https://doi.org/10.1002/dvdy.151
    1. Wilson C, Goberdhan DCI, Steller H. Dror, a potential neurotrophic receptor gene, encodes a Drosophila homolog of the vertebrate Ror family of Trk‐related receptor tyrosine kinases. Proc Natl Acad Sci U S A. 1993;90(15):7109‐7113. https://doi.org/10.1073/pnas.90.15.7109
    1. Forrester WC, Dell M, Perens E, Garriga G. A C. elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division. Nature. 1999;400(6747):881‐885. https://doi.org/10.1038/23722

MeSH terms

Substances

LinkOut - more resources